Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation

Michael Y. Shapira; Igor B. Resnick; Sunwen Chou; Avidan U. Neumann; Nell S. Lurain; Thomas Stamminger; Orit Caplan; Niveen Saleh; Thomas Efferth; Manfred Marschall; Dana G. Wolf

doi:10.1086/587106

Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation

Michael Y. Shapira
, Igor B. Resnick
, Sunwen Chou
, Avidan U. Neumann
, Nell S. Lurain
, Thomas Stamminger
, Orit Caplan
, Niveen Saleh
, Thomas Efferth
, Manfred Marschall
, Dana G. Wolf

Research output: Contribution to journal › Article › peer-review

144 Scopus citations

Abstract

This is the first report of treatment of cytomegalovirus infection with artesunate, for a stem cell transplant recipient with a newly identified foscarnet-resistant and ganciclovir-resistant DNA polymerase L776M mutation. Artesunate treatment resulted in a 1.7-2.1-log reduction in viral load by treatment day 7, with a viral half-life of 0.9-1.9 days, indicating a highly effective block in viral replication.

Original language	English
Pages (from-to)	1455-1457
Number of pages	3
Journal	Clinical Infectious Diseases
Volume	46
Issue number	9
DOIs	https://doi.org/10.1086/587106
State	Published - 1 May 2008
Externally published	Yes

Access to Document

10.1086/587106

Cite this

Shapira, M. Y., Resnick, I. B., Chou, S., Neumann, A. U., Lurain, N. S., Stamminger, T., Caplan, O., Saleh, N., Efferth, T., Marschall, M., & Wolf, D. G. (2008). Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clinical Infectious Diseases, 46(9), 1455-1457. https://doi.org/10.1086/587106

@article{ef0cbb2d194643f9bb7ad27145c71b22,

title = "Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation",

abstract = "This is the first report of treatment of cytomegalovirus infection with artesunate, for a stem cell transplant recipient with a newly identified foscarnet-resistant and ganciclovir-resistant DNA polymerase L776M mutation. Artesunate treatment resulted in a 1.7-2.1-log reduction in viral load by treatment day 7, with a viral half-life of 0.9-1.9 days, indicating a highly effective block in viral replication.",

author = "Shapira, \{Michael Y.\} and Resnick, \{Igor B.\} and Sunwen Chou and Neumann, \{Avidan U.\} and Lurain, \{Nell S.\} and Thomas Stamminger and Orit Caplan and Niveen Saleh and Thomas Efferth and Manfred Marschall and Wolf, \{Dana G.\}",

year = "2008",

month = may,

day = "1",

doi = "10.1086/587106",

language = "אנגלית",

volume = "46",

pages = "1455--1457",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "9",

}

Shapira, MY, Resnick, IB, Chou, S, Neumann, AU, Lurain, NS, Stamminger, T, Caplan, O, Saleh, N, Efferth, T, Marschall, M & Wolf, DG 2008, 'Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation', Clinical Infectious Diseases, vol. 46, no. 9, pp. 1455-1457. https://doi.org/10.1086/587106

TY - JOUR

T1 - Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation

AU - Shapira, Michael Y.

AU - Resnick, Igor B.

AU - Chou, Sunwen

AU - Neumann, Avidan U.

AU - Lurain, Nell S.

AU - Stamminger, Thomas

AU - Caplan, Orit

AU - Saleh, Niveen

AU - Efferth, Thomas

AU - Marschall, Manfred

AU - Wolf, Dana G.

PY - 2008/5/1

Y1 - 2008/5/1

N2 - This is the first report of treatment of cytomegalovirus infection with artesunate, for a stem cell transplant recipient with a newly identified foscarnet-resistant and ganciclovir-resistant DNA polymerase L776M mutation. Artesunate treatment resulted in a 1.7-2.1-log reduction in viral load by treatment day 7, with a viral half-life of 0.9-1.9 days, indicating a highly effective block in viral replication.

AB - This is the first report of treatment of cytomegalovirus infection with artesunate, for a stem cell transplant recipient with a newly identified foscarnet-resistant and ganciclovir-resistant DNA polymerase L776M mutation. Artesunate treatment resulted in a 1.7-2.1-log reduction in viral load by treatment day 7, with a viral half-life of 0.9-1.9 days, indicating a highly effective block in viral replication.

UR - https://www.scopus.com/pages/publications/42549168601

U2 - 10.1086/587106

DO - 10.1086/587106

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 18419454

AN - SCOPUS:42549168601

SN - 1058-4838

VL - 46

SP - 1455

EP - 1457

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 9

ER -

Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation

Abstract

Access to Document

Other files and links

Fingerprint

Cite this